Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple IV drug shorten labor after water breaks?

NCT ID NCT07517796

Symptom relief Sponsor: Western Galilee Hospital-Nahariya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving the drug papaverine through an IV can help women whose water has broken (but labor hasn't started yet) deliver faster. About 110 pregnant women at term will receive either papaverine or a placebo 12 hours after their water breaks. The goal is to see if the drug reduces the time from water breaking to delivery and improves outcomes for both mother and baby.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
papaverine
What this could lead to
If it works, this could offer a simple, low-cost way to shorten labor after water breaks at term, potentially reducing infection risk and the need for cesarean delivery.
What could go wrong
This is a small, early-phase trial with only 110 participants, so results may not apply widely. Papaverine may not speed up labor more than placebo, and there is a risk of side effects like low blood pressure or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Singleton pregnancy * Term gestation (37-42 weeks) * Term PROM prior to active labor * Duration of PROM \<12 hours at enrollment * Bishop score \<8 * Cephalic presentation * Viable fetus with reassuring fetal heart rate Exclusion Criteria: * • Multiple gestation * Previous cesarean delivery * Major fetal anomalies * Contraindication to vaginal delivery * Meconium-stained amniotic fluid * Suspected chorioamnionitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Premature rupture of membranes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fetal Membranes, Premature Rupture preterm premature rupture of the membranes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Premature rupture of membranes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Galilee Medical Center

    RECRUITING

    Nahariya, Israel, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.